Lilly's Mounjaro Demonstrates Superior Efficacy in Head-to-Head Trials Against Diabetes Competitors
• Eli Lilly's Mounjaro (tirzepatide) has shown superior efficacy in reducing HbA1c levels and body weight compared to Novo Nordisk's Ozempic in clinical trials, offering new hope for the 35 million Americans with type 2 diabetes.
• As the first dual-action medication that stimulates both GLP-1 and GIP receptors, Mounjaro achieved mean HbA1c reductions of 1.7% to 2.4% across trials, with participants losing between 12-25 pounds depending on dosage.
• Recently launched in India following CDSCO approval, Mounjaro is now indicated for both chronic weight management in adults with obesity or overweight with comorbidities, and as an adjunct treatment for type 2 diabetes mellitus.
Indian Pharma Companies to Launch Generic Empagliflozin at 90% Lower Cost
• Several Indian pharmaceutical companies are preparing to launch generic versions of Empagliflozin following Boehringer Ingelheim's patent expiry on March 11, potentially transforming diabetes treatment accessibility.
• Mankind Pharma plans to offer the diabetes medication at approximately Rs 6 per tablet, a 90% reduction from the innovator's price of Rs 60, with most generic versions expected to cost between Rs 9-14 per tablet.
• The affordable generics will significantly reduce therapy costs for India's 10.1 crore diabetic patients, most of whom pay out-of-pocket, while still providing benefits for heart failure and chronic kidney disease management.
Sonnet BioTherapeutics Advances Pipeline with Clinical Data and Strategic Partnerships
• Sonnet BioTherapeutics reported stable disease in 48% of evaluable monotherapy patients in the Phase 1 SB101 trial for SON-1010 (IL12-FHAB).
• Clinical trials evaluating SON-1010 in combination with Atezolizumab for Platinum-Resistant Ovarian Cancer (PROC) and trabectedin for advanced soft-tissue sarcomas (STS) are progressing.
• A licensing agreement was initiated in India for SON-080 in October 2024, focusing on Diabetic Peripheral Neuropathy (DPN) and reorganizing the leadership team.
• Sonnet anticipates initiating a clinical trial for SON-1210 with chemotherapy for advanced solid tumors and metastatic pancreatic cancer in H1 2025.
© Copyright 2025. All Rights Reserved by MedPath